TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03121170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave therapy
Description: Intervention group is by extracorporeal shock wave therapy.A radial shock wave device (EMS Swiss Dolor, Munich, Germany) was used. Radial shock wave is created ballistically with the pressurized air source accelerating a bullet to strike a metal applicator. The kinetic energy produced is transformed into radially expanding shock waves from the application site into the tissue to be treated. The treatment of area is lower abdomen which has some acupuncture points such as Shenque(CV8) ,Qihai(BL24), Guanyuan(CV4), Zhongji(CV3), Tianshu(ST25), Guilai(ST29) and Zigong(EX-CA1) at the right and left sides of the lower abdomen. All acupuncture points should be placed according to participants' feedback during treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave therapy
Description: Intervention group is by extracorporeal shock wave therapy.A radial shock wave device (EMS Swiss Dolor, Munich, Germany) was used. Radial shock wave is created ballistically with the pressurized air source accelerating a bullet to strike a metal applicator. The kinetic energy produced is transformed into radially expanding shock waves from the application site into the tissue to be treated. The treatment of area is lower abdomen which has some acupuncture points such as Shenque(CV8) ,Qihai(BL24), Guanyuan(CV4), Zhongji(CV3), Tianshu(ST25), Guilai(ST29) and Zigong(EX-CA1) at the right and left sides of the lower abdomen. All acupuncture points should be placed according to participants' feedback during treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hot compress paste
Description: Hot compress pastes will be sticked on the lower abdomen.
Study: NCT00990522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debridement
Description: There will be two (2) subject groups in the study. Subjects will be randomized into either the monthly debridement group or the weekly debridement group.
Study: NCT01335360

Intervention type: DRUG
Intervention: Nevirapine
Description: 200mg twice daily of nevirapine

Intervention type: DRUG
Intervention: Nevirapine
Description: 200mg twice daily of nevirapine

Intervention type: DRUG
Intervention: Nevirapine
Description: 200mg twice daily of nevirapine
Study: NCT03362827

Intervention type: OTHER
Intervention: Chronic low back pain patients
Description: People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.

Intervention type: OTHER
Intervention: Subjects without chronic low back pain
Description: These participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
Study: NCT01997333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study: NCT00743626

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic cervical cancer screening tests (Pap smear, HPV and/or p16)
Description: If positive (Pap smear, HPV and/or p16) patients will be scheduled for 3 colposcopy follow up visits (1,12,18 months)
Study: NCT02311634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical pudendal nerve stimulation
Description: Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ES
Description: A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
Study: NCT02504424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroForm Tissue Expander
Description: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
Study: NCT03175822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Arts Training
Description: The art training program has been designed as a drawing program and focuses on basic visual art concepts (the elements \[e.g., colour and line\] and principles \[e.g., proportion and balance\] of design). Each week has a different activity and a different focus (one activity per week focusing on one element and principle of design). Each art training program will occur one hour per day, two days per week, for eight weeks. The art training program will take place at the participants' respective dementia care location in an area separate from waitlist control participants and uninvolved clients. All art programs are free for participants.
Study: NCT00623350

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone
Description: Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two way audio/video telemedicine consult
Description: Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
Study: NCT00543842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Starting Dose 650 mg/m\^2 By Mouth Twice Daily Monday-Friday x 6 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Starting Dose 50 mg By Mouth Daily Weeks 1-3

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: At least 8 weeks after radiation therapy, surgical removal of rectal tumor
Study: NCT02815982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NOURISH-T
Description: Overweight/obesity family intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Publicly available overweight/obesity materials
Study: NCT02657109

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy procedure
Description: physiotherapy exercises conducted in early way for the rehabilitation of patients in the postoperative period of cardiac valve replacement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy procedure
Description: physiotherapy exercises conducted in early way for the rehabilitation of patients in the postoperative period of cardiac valve replacement.
Study: NCT02083822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: term MRI, executive EF functions testing
Description: An MRI will be realized at term born between 25 and 32 weeks GA
Study: NCT03234010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21097
Description: An electronic cigarette
Study: NCT03967197

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray
Description: Physiologic saline spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Lidocaine hydrochloride 10% spray
Study: NCT01359163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etynodiol diacetate
Description: tablet, 0.5 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etynodiol diacetate
Description: tablet, 0.5 mg, single dose
Study: NCT01196364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: water with noncalorie sweetener
Study: NCT01577550

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, i.v.
Description: Single i.v. administration of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (high s.c. dose)
Description: Single high s.c. dose BI 655066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (low i.v. dose)
Description: Single low i.v. dose BI 655066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (high medium i.v. dose)
Description: Single high medium i.v. dose BI 655066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (very low i.v. dose)
Description: Single very low i.v. dose BI 655066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (low s.c. dose)
Description: Single low s.c. dose BI 655066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (high i.v. dose)
Description: Single high i.v. dose BI 655066

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, s.c.
Description: Single s.c. administration of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (low medium i.v. dose)
Description: Single low medium i.v. dose BI 655066
Study: NCT04498117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: 2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: 2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2, every 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2, every 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: AUC 6 IV Day 1 x 6 cycles (every 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 IV Day 1 x 6 cycles (every 21 days)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5-6 IV Day 1 x 6 cycles (every 21 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: AUC 5-6 IV Day 1 x 6 cycles (every 21 days)
Study: NCT05257057

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemical staining
Description: Immunohistochemistry will be performed on the endometrial tissue specimens
Study: NCT01356212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
Study: NCT03953612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone (PREG)
Description: 2 doses of PREG (300 or 500 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone (PREG)
Description: 2 doses of PREG (300 or 500 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo
Study: NCT04348695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib plus simvastatin
Description: Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Patients will receive treatment according to usual clinical practice in the participant site.
Study: NCT04084457

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wild Blueberry powder
Description: Powdered extract obtained from wild blueberries. A daily administration of 27g wild blueberry powder will be administered.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical formulation as the treatment matched for fibre and vitamin C
Study: NCT03610152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital Policy change
Description: Implementation of a hospital wide policy whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologist based on their clinical assessment of the patient.
Study: NCT00860392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer (13-C(4)-BHB)
Description: A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
Study: NCT03509857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BUZZY(tm)
Description: Risks associated with the BUZZY(tm) device The intervention group will receive vibration only, with application of the BUZZY device just proximal to the intravenous infusion site immediately before and during propofol infusion.~There are no known risks for the use of the BUZZY(tm) device, which is registered as an FDA class III device (therapeutic massager).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Intervention
Description: No intervention
Study: NCT04542057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine
Description: Dosage Formulation:~Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Formulation:~Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks
Study: NCT00754650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a sterile liquid in single-use vials.
Study: NCT03210792

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Rib Splint
Description: Investigators randomly apply handmade Rib Splint or manufactured Rib Splint to subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Rib Splint
Description: Investigators randomly apply handmade Rib Splint or manufactured Rib Splint to subjects.
Study: NCT02797197

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: handgrip strength test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study: NCT04844060

Intervention type: OTHER
Intervention: Lumbar punction
Description: Lumbar punction
Study: NCT02852577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam
Description: Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Administration of paroxetine once a day, flexible dose (10 - 40 mg/day), for 36 months. If no remission after 8 weeks augmentation with clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 34 months.
Study: NCT05597319

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Liver resection, different kind of according to pathology

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Liver resection, different kind of according to pathology
Study: NCT01196364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: water with noncalorie sweetener

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity: With noncalorie sweetener or glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity: With noncalorie sweetener or glucose
Study: NCT02954289

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary intervention
Description: Session 1:The Breakfast Club: ways to increase the healthiness of breakfast and all meals.~Session 2: Calcium and Vitamin D -Keys to Bone Health~Session 3: Fruits and Veggies -Your New Best Friends~Session 4: Let's Talk About Fat~Session 5: Shopping Therapy~Session 6: Celebrity Chefs Share Their Secrets
Study: NCT01323790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 12.5 mg oral tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 25 mg oral tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to NKTR-118
Study: NCT03312621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Care Transition Care Coordination
Description: These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
Study: NCT00003088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: given IV
Study: NCT03562793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE)
Description: . COOPERATE seeks to improve patient activation in minority Veterans with chronic pain by focusing on two major skill sets: 1) goal clarification and prioritization, and 2) communication skills (Table 1). By understanding, clarifying, and prioritizing goals, and having the skills to communicate their goals, priorities, and preferences to providers, Veterans will gain knowledge, confidence, and skills to be actively involved in managing their chronic pain. The intervention consists of 6 total sessions delivered individually over 12 weeks: 4 sessions focused on teaching skills related to goal clarification/prioritization and communication (30-minutes each), delivered weekly for the first 4 weeks, plus 2 booster sessions (20-25 minutes each) delivered once per month for the next 2 months.
Study: NCT00003088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: given IV
Study: NCT03857282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercises
Description: 5 to 10 min warm up exercises than 30min bicycle exercise and 5 to 10 min cool down exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Exercises
Description: 5 to 10 min warm up exercises and 30 min Tai Chi exercises and than than 5 to 10 min cool down exercises.
Study: NCT02397876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partially Hydrolyzed Whey formula
Description: Patients who tolerate partially hydrolyzed whey formula will be continued on this formula for two years. Patients who do not tolerate the formula will be continued on their prior diet of cows milk avoidance.
Study: NCT02336646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic MSC
Description: Hypoxia-cultured human bone marrow derived mesenchymal stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic MSC
Description: Hypoxia-cultured human bone marrow derived mesenchymal stem cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT03924687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) bibliotherapy for chronic pain
Description: The intervention consisted of the book Libérez-vous de la douleur par la méditation et l'ACT (Dionne, 2014) and a participant workbook, along with two phone calls of approximately 15 minutes each and weekly e-mails presenting the week's content. Participants also had access to audio meditation exercises on the book's website (http://liberezvousdeladouleur.com/meditations/).
Study: NCT01321827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach